• Ascendis Pharma A/S ASND.OQ reported a quarterly adjusted loss of €1.72​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of €-2.88. The mean expectation of thirteen analysts for the quarter was for a loss of €1.74 per share. Wall Street expected results to range from $-2.14 to €-1.23 per share.

• Revenue rose 20.4% to $57.83 million from a year ago; analysts expected €82.36 million.

• Ascendis Pharma A/S's reported EPS for the quarter was a loss of €1.72​.

• The company reported a quarterly loss of €99.2 million.

• Ascendis Pharma A/S shares had fallen by 16.8% this quarter and lost 1.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 44.4% in the last three months.​

• In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Ascendis Pharma A/S is $191.00

This summary was machine generated from LSEG data November 15 at 02:04 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)